Larry M. Simonsmeier Writing Award
The American Society for Pharmacy Law (ASPL) is a nationwide organization with the purposes of: (i) furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues ("Pharmacy Law"); (ii) communicating accurate legal educational information; and (iii) providing education opportunities for pharmacists, attorneys, and others who are interested in Pharmacy Law.
ASPL recognizes outstanding scholarship related to Pharmacy Law with the Simonsmeier Award. The Award recognizes an outstanding paper relating to the interests of ASPL published during the prior two years (2013-2015). The 2016 Award includes an honorarium plus support for travel to the ASPL Developments in Pharmacy Law Seminar XXVII in Austin, Texas, November 9-13, 2016.
The Award is named in honor of the late Larry Simonsmeier (1944-2009), who was a pharmacist and attorney, professor and dean of Washington State University College of Pharmacy, president of ASPL, and editor of the Rx Ipsa Loquitur for more than twenty years.
Papers related to Pharmacy Law, as defined above, published in or accepted for publication in any English-language peer-reviewed journal (including law reviews) during the period from January 2013 through December 2015 are eligible. Interested parties are invited to nominate published papers written by themselves or other authors. Authors may submit manuscripts that are in press.
Submission of Nominations
Nominations should provide the name, address, daytime telephone number, and e-mail address of the nominator, a reprint of the full paper, and a complete journal citation for the paper being nominated. If an author is submitting a manuscript that is in press, the copy of the manuscript should be accompanied by documentation from the journal editor of the status of the paper, and should include contact information for the journal editor. The deadline for submission of nominations for the Larry M. Simonsmeier Award is June 30, 2016.
Nominations should be addressed to:
Education & Scholarship Committee
Questions may be directed to ASPL at:
October 24, 2016
Cigna enters into settlement with NY AG, will no longer require prior authorization for buprenorphine treatment for opioid addiction
The Wall Street Journal reported on October 21 that the health insurer, Cigna Corp., will discontinue requiring prior authorization for its beneficiaries to receive office-based narcotic maintenance treatment with buprenorphine (e.g., Suboxone®), as a result of a settlement with the New York Attorney General's Office following a request by the AG to "address concerns about barriers to treatment." The prior authorization process required physicians to respond to "numerous questions" and sometimes delayed treatment by "several days." The change will become effective nationwide for all of Cigna’s commercial plans. [Whalen J, Mathews AW. Cigna ends preauthorization for medication to treat opioid addiction. Wall Street Journal 2016 Oct 21; http://on.wsj.com/2eEbMxg]
2016 DPLXXVII Seminar
November 10-13, 2016